Natco And MSN Battle Chugai Over Alectinib In India
Originator Pursues Alecensa Patent Infringement Charges In Delhi High Court
Roche affiliate Chugai has moved court in India seeking to restrain Natco and MSN Laboratories over alleged infringement of its patent concerning Alecensa. The Indian firms, however, contend their actions fall under the ambit of the country’s “Bolar exemption” provision.
You may also be interested in...
Just months ahead of the patent expiry for Votrient in India, Novartis hauls alleged infringer MSN Laboratories to court, which has bound the Indian firm by its pre-launch assurance for the anticancer therapy.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
Top executives at leading local and foreign drug firms in India by and large earned more in 2020-21, while differentials in CEO to median employee remuneration remained stark. With increasing scrutiny by shareholders and lawmakers, experts suggest that pharma should be more mindful of balancing “adequate” C-suite compensation and glaring inequalities.